JNJ vs V: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Visa Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
VS
Visa Inc. · Financial Services
$327.24
+27.8% upside to fair value
Grade A
High Quality
QuantHub Verdict
V has more upside to fair value
(+27.8%).
V trades at a lower forward P/E
(28.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
V |
| Current Price |
$253.85 |
$327.24 |
| Fair Value Estimate |
$198.76 |
$418.15 |
| Upside to Fair Value |
-21.7%
|
+27.8%
|
| Market Cap |
$611.1B |
$627.3B |
| Forward P/E |
29.3x
|
28.2x
|
| EV / EBITDA |
19.2x
|
22.6x
|
| Price / Sales |
6.3x
|
14.6x
|
| Price / FCF |
34.3x
|
29.6x
|
| Revenue Growth YoY |
+9.9%
|
+17.1%
|
| Gross Margin |
69.1%
|
81.3%
|
| Operating Margin |
26.9%
|
61.1%
|
| Return on Equity |
26.3%
|
58.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.91%
|
3.38%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
Visa Inc. operates a global payments network that facilitates electronic funds transfers worldwide, primarily through credit and debit cards. The company benefits from a very strong and widening moat driven by its extensive global card network and acceptance infrastructure, supported by a shareholder-friendly capital allocation policy including high buybacks and dividends. Visa's business quality…
Accumulation Zones
| Metric |
JNJ |
V |
| Zone Low |
$149.07 |
$313.61 |
| Zone High |
$168.95 |
$355.43 |
| In Buy Zone? |
No
|
Yes
|